Results 31 to 40 of about 4,535 (170)

Absolute Risk Reductions in COVID-19 Antiviral Medication Clinical Trials

Pharmacoepidemiology, 2023
COVID-19 antiviral medications approved or authorized for emergency use by the U.S. Food and Drug Administration are reported to have high efficacy in preventing severe illness, hospitalizations, and deaths.
Ronald B. Brown
doaj   +1 more source

A Rare Case of Paxlovid-Induced Pancreatitis

Cureus, 2023
Acute pancreatitis can result secondary to an inflammatory cascade due to an insult to the pancreatic parenchyma, whether it be from infections, medications, etc. We present a case of a 37-year-old male with acute pancreatitis after being started on Paxlovid, a combination drug containing Nirmatrelvir and Ritonavir, for COVID-19 treatment.
Zaidi, Syed Muhammad Hussain, Iskander, Peter A, Ahmed, Khalid, Jaber, Fouad, Paz, Merlin, Khan, Ali, Malik, Fahad, Aloysius, Mark M   +7 more
openaire   +2 more sources

Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study

Frontiers in Pharmacology, 2022
Background: Our previous studies have shown that Yindan Jiedu granules (YDJDG) can effectively treat coronavirus disease 2019 (COVID-19); however, the high infectivity and the immune escape potential of the Omicron variant BA.2 make it more difficult to ...
Ying Feng, Yao Liu, Long Liu, Yao Liu, Yuyong Jiang, Yixin Hou, Yang Zhou, Rui Song, Xiaoyou Chen, Xianbo Wang   +9 more
doaj   +1 more source

Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant

Frontiers in Pediatrics, 2023
ObjectiveTo summarize the clinical characteristics of children with hematological malignancies co-infected with novel coronavirus and explore the safety and effectiveness of Paxlovid treatment.MethodsFrom December 10, 2022, to January 20, 2023, the ...
Yixian Li, Yong Liu, Luping Wen, Hui Chen, Wenqing Wang, Mengyao Tian, Yucai Cheng, Hongman Xue, Chun Chen   +8 more
doaj   +1 more source

REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS

International Journal of Infectious Diseases, 2023
Intro: On May 24, 2022, the CDC issued a healthcare advisory after reports of COVID-19 symptoms returning (COVID-19 rebound) in certain patients two to eight days after treatment with Paxlovid (Ritonavir-Boosted Nirmatrevir). We describe two patients who
P. Periyasamy, T. Li Fen, N. Kori, U.A. Zainulabid   +3 more
doaj   +1 more source

RECOVER Query: Paxlovid

, 2022
The overall goals of this query are to 1) characterize the growth in patients receiving Paxlovid over time and 2) examine Paxlovid use by patient characteristics, including by acute SARS CoV-2 infection profile and healthcare utilization. Patients with a COVID index date or a visit date between 12/1/2021 (7 days before EUA) and 5/30/2022 are included ...
openaire   +1 more source

Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico

Journal of Infection and Public Health
Background: Information on Paxlovid™ effectiveness must be monitored and updated in real world scenarios. Our research question was what is the effectiveness of Paxlovid™ in adult patients with COVID-19?
María Elena Camacho Moll, Ana Maria Salinas Martínez, Minna Wu, Gloria Navarrete Floriano, Juan Carlos Romo Salazar, Jorge Eleazar Cruz Luna, Mario Bermúdez de León   +6 more
doaj   +1 more source

Ondansetron in a Paxlovid Intolerant Man

Austin Journal of Clinical Case Reports, 2022
A symptomatic 22-year-old man, unvaccinated and living with high-risk elder parents, was prescribed nirmatrelvir/ritonavir (Paxlovid®) after testing positive for COVID-19. The patient developed persistent moderate to severe nausea after the first dose, progressing to severe nausea and several vomiting episodes after the second dose.
LG, Cubeddu, TM, Dalley, LX, Cubeddu
openaire   +1 more source

Beyond Simple Mimicry: Next‐Generation Geometric Architectures and Future Paradigms in Small‐Molecule and Macrocyclic Peptidomimetics

Angewandte Chemie International Edition, EarlyView.
Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee, Sumin Son, Jeong Yeon Yoo, Ji Hyae Lee, Meehyun Chun, Seung Bum Park   +5 more
wiley   +1 more source

A real‐world analysis of AI chatbot performance for medicines information enquiries

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background The provision of medicines information (MI) services requires interpretation and clinical judgement of complex scenarios by pharmacists. To date, few studies have assessed the performance of artificial intelligence (AI) chatbots to assist pharmacists providing MI advice.
Duncan Yorkston, Tracey Borrie, Paul Chin   +2 more
wiley   +1 more source